Valuation : PharmaEngine, Inc.

Market Cap 8.29B 261M 225M 212M 193M 361M 24.65B 364M 2.51B 975M 12.61B 980M 959M 41.41B P/E 2024
7.42x
P/E 2025 26.2x
Enterprise Value 3.62B 114M 98.2M 92.5M 84.28M 158M 10.75B 159M 1.1B 425M 5.5B 427M 418M 18.06B EV / Sales 2024
3.61x
EV / Sales 2025 5.97x
Free-Float
61.29%
Yield 2024
6.64%
Yield 2025 2.84%
1 day-1.20%
1 week-2.20%
Current month-2.20%
1 month-6.03%
3 months+6.26%
6 months-11.23%
Current year-18.04%
1 week 57.4
Extreme 57.4
60.5
1 month 57.4
Extreme 57.4
64.7
Current year 53
Extreme 53
74
1 year 53
Extreme 53
74.4
3 years 53
Extreme 53
123
5 years 53
Extreme 53
150.5
10 years 33.1
Extreme 33.1
212.51
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 17/05/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 19/01/2018
Director/Board Member - 15/05/2018
Director/Board Member - 13/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
-1.20%-2.20%-12.44%-35.24% 265M
+0.97%-1.75%+2.17%+18.46% 49.74B
-0.30%-2.88%+429.29%+521.04% 44.98B
+2.13%+0.89%+43.59%+19.44% 42.52B
+0.87%-3.73%+8.96%+76.62% 40.78B
-0.90%-1.74%+15.20%+48.44% 32.89B
+2.71%+6.82% - - 17.09B
+1.68%-4.20%+25.28%+123.70% 16.28B
+1.70%-1.75%+12.00%+28.50% 14.4B
+3.34%-1.13%+80.94%+42.82% 13.48B
Average +1.10%-2.64%+67.22%+93.75% 27.24B
Weighted average by Cap. +1.01%-2.25%+93.25%+128.82%

Financials

2024 2025
Net sales 2.52B 79.44M 68.53M 64.56M 58.82M 110M 7.5B 111M 764M 297M 3.84B 298M 292M 12.6B 911M 28.69M 24.75M 23.32M 21.25M 39.71M 2.71B 40.01M 276M 107M 1.39B 108M 105M 4.55B
Net income 1.75B 55.13M 47.56M 44.8M 40.82M 76.3M 5.21B 76.87M 530M 206M 2.66B 207M 202M 8.75B 388M 12.2M 10.53M 9.92M 9.04M 16.89M 1.15B 17.02M 117M 45.57M 589M 45.83M 44.82M 1.94B
Net Debt -3.85B -121M -105M -98.6M -89.83M -168M -11.46B -169M -1.17B -453M -5.86B -456M -446M -19.25B -4.67B -147M -127M -120M -109M -204M -13.9B -205M -1.42B -550M -7.11B -553M -541M -23.35B
Logo PharmaEngine, Inc.
PharmaEngine Inc is a Taiwan-based company primarily engaged in new drug development. The main business is the research and development of various cancer drugs. ONIVYDE is a novel and stable encapsulated form of the marketed chemotherapy drug irinotecan in a long-circulating nanoliposome for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. It has received marketing approvals in Taiwan, the United States, the European Union, Singapore, South Korea, Japan, China and other regions. PEP07, a checkpoint kinase 1 (CHK1) inhibitor, which targets the deoxyribonucleic acid damage response (DDR) network, is in Phase 1 clinical trial stage and its target is to treat hematologic cancers such as acute myeloid leukemia (AML) and mantle cell lymphoma (MCL), and solid tumors.
Employees
45
Date Price Change Volume
02/09/26 NT$57.70 -1.20% 287,700
01/09/26 NT$58.40 -1.02% 205,230
31/08/26 NT$59.00 -1.67% 203,597
28/08/26 NT$60.00 -0.83% 159,389
27/08/26 NT$60.50 +0.67% 200,382
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4162 Stock